BCAL Diagnostics (ASX:BDX) - CEO , Dr John Hurrell
CEO , Dr John Hurrell
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Breast cancer screening and diagnostic company BCAL Diagnostics (BDX) names Dr John Hurrell as its new Chief Executive Officer
  • The incoming CEO’s remuneration is set at $300,000 per annum, plus a short-term incentive of 30 per cent of total employment cost for 2022
  • Dr Hurrell will commence in his new role on February 14, with his time divided between Australia and the US
  • BDX shares last traded at 12.5 cents at 1:05 pm AEDT

Breast cancer screening and diagnostic company BCAL Diagnostics (BDX) has appointed Dr John Hurrell as its new Chief Executive Officer.

The company said Dr Hurrell, whose career spans 35 years, brings with him a wealth of experience in commercialising multiple products and services in life sciences and diagnostics.

He joins BCAL from JanaCare, a remote chronic disease patient management company focused on kidney disease and diabetes, where he held the role of Chief Commercial Officer.

Dr Hurrell’s remuneration will be $300,000 per annum, plus a short-term incentive of 30 per cent of total employment cost (TEC) for this year and 50 per cent of TEC for 2023.

He takes the reins at BCAL as the company progresses its vision to develop a non-invasive blood test for the detection of breast cancer.

BCAL Executive Chair Jayne Shaw said the company was excited to appoint a candidate as experienced and suitably skilled as Dr Hurrell.

“He has a strong track record in starting, building and improving the profitability, performance and value of life science and healthcare companies, demonstrated by his many years across international roles,” Ms Shaw said.

“We believe this will be ideal for BCAL as we continue to drive development of our technology to provide early and accurate breast cancer diagnosis to improve outcomes for patients.”

The incoming CEO will commence in his new role on February 14, with his time divided between Australia and the US.  He will manage the current scientific and clinical activities based in Sydney, while preparing the company for future product launch in North America.

BDX shares were trading almost steady at 12.5 cents at 1:05 pm AEDT.

BDX by the numbers
More From The Market Herald
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece
Orexplore Technologies (ASX:OXT) - Chair, Dr Alan Bye

" Orexplore Technologies (ASX:OXT) debuts on ASX

Mineral scanning technology company Orexplore Technologies (ASX:OXT) has commenced trading on the ASX today under the…